- Home
- PONY vs TLX Comparison
PONY vs TLX Comparison
Compare PONY & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PONY
- TLX
- Stock Information
- Founded
- PONY 2016
- TLX 2015
- Country
- PONY China
- TLX Australia
- Employees
- PONY N/A
- TLX N/A
- Industry
- PONY
- TLX Biotechnology: Pharmaceutical Preparations
- Sector
- PONY
- TLX Health Care
- Exchange
- PONY NYSE
- TLX Nasdaq
- Market Cap
- PONY 4.9B
- TLX 5.7B
- IPO Year
- PONY 2024
- TLX N/A
- Fundamental
- Price
- PONY $11.83
- TLX $17.15
- Analyst Decision
- PONY Strong Buy
- TLX Strong Buy
- Analyst Count
- PONY 3
- TLX 2
- Target Price
- PONY $19.20
- TLX $22.00
- AVG Volume (30 Days)
- PONY 14.5M
- TLX 27.1K
- Earning Date
- PONY 08-15-2025
- TLX 01-01-0001
- Dividend Yield
- PONY N/A
- TLX N/A
- EPS Growth
- PONY N/A
- TLX 798.14
- EPS
- PONY N/A
- TLX 0.09
- Revenue
- PONY $76,483,000.00
- TLX $484,687,790.00
- Revenue This Year
- PONY $11.57
- TLX N/A
- Revenue Next Year
- PONY $69.14
- TLX N/A
- P/E Ratio
- PONY N/A
- TLX $176.39
- Revenue Growth
- PONY N/A
- TLX 55.85
- 52 Week Low
- PONY $4.11
- TLX $13.61
- 52 Week High
- PONY $23.88
- TLX $30.36
- Technical
- Relative Strength Index (RSI)
- PONY N/A
- TLX N/A
- Support Level
- PONY N/A
- TLX N/A
- Resistance Level
- PONY N/A
- TLX N/A
- Average True Range (ATR)
- PONY 0.00
- TLX 0.00
- MACD
- PONY 0.00
- TLX 0.00
- Stochastic Oscillator
- PONY 0.00
- TLX 0.00
About PONY PONY AI INC SPON ADS EACH REP 1 COM CL A
Pony AI Inc is an artificial intelligence technology company that is principally engaged in the operation and development of autonomous vehicles. It operates fully driverless robotaxis through the PonyPilot mobile app in Beijing, Shanghai, Guangzhou, and Shenzhen. The company operates a fleet of robotaxis. The Group conducts its operations mainly in the People's Republic of China (PRC) and the United States of America (U.S.) through subsidiaries. Key revenue is generated from the People's Republic of China.
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.